1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

European Pharma Pushes Back Against ‘Discriminatory’ New EU Drug Pollution Proposals

European Commission Insists Its Measures Against Pharmaceutical Pollution Have Wide Support

 
• By Rosalind Rei

Medicines for Europe, along with EFPIA and the AESGP, say that the ‘polluter pays’ principle behind proposed new European rules on wastewater treatment would saddle pharmaceutical manufacturers with costs that “jeopardize patient access.”

Four wastewater treatment sedimentation pools containing blue-ish liquid, seen from above
Drug Producers Would Have To Pay Wastewater Plants According To Products' Polluting Potential • Source: Shutterstock

Medicines for Europe, along with brand industry association the European Federation of Pharmaceutical Industries and Associations and self-care body the AESGP, have released a joint statement criticizing new European Commission proposals for tackling pharmaceutical wastewater pollution from drugs excreted at the end of their product lives.

The statement was in response to the EC’s proposed revisions to the 1991 Urban Wastewater Treatment Directive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

More from Policy & Regulation

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.